In vitro Anti-atherothrombosis Activity of Nigella sativa Oil, Phytol and their Combinations
By: Muhammad Torequl Islam
.
Contributor(s): Molla, Shamim.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2019Edition: Vol.53(4), Oct-Dec.Description: 670-674p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Background: Black seed oil and Phytol (PHY) are evident for their promising biological effects in various test systems. Aim: This study evaluates anti-atherothrombosis activity of Nigella sativa oil (NSO) and Phytol (PHY). Materials and Methods: The clotlysis activity of the NSO and/or PHY has been investigated by taking Streptokinase (SK) as a standard clotlysis drug. Results: The results suggest that the NSO and PHY exhibited a concentration-dependent clotlysis activity in human clotted blood. The highest clotlysis of the NSO and PHY was seen by 57.83 ± 0.23% and 53.05 ± 2.93% with 80 μL and 150 μg per tube, respectively. NSO co-treated with PHY showed a better clotlysis capacity than the NSO and PHY. The vehicle showed negligible clotlysis (2.86 ± 4.33%) capacity, while the standard SK (100 I.U.) showed 78.96 ± 1.08% clotlysis activity. Conclusion: NSO and/or PHY exhibited clotlysis activity in human clotted blood in in vitro.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2021152 |
Background: Black seed oil and Phytol (PHY) are evident for their promising biological effects in various test systems. Aim: This study evaluates anti-atherothrombosis activity of Nigella sativa oil (NSO) and Phytol (PHY). Materials and Methods: The clotlysis activity of the NSO and/or PHY has been investigated by taking Streptokinase (SK) as a standard clotlysis drug. Results: The results suggest that the NSO and PHY exhibited a concentration-dependent clotlysis activity in human clotted blood. The highest clotlysis of the NSO and PHY was seen by 57.83 ± 0.23% and 53.05 ± 2.93% with 80 μL and 150 μg per tube, respectively. NSO co-treated with PHY showed a better clotlysis capacity than the NSO and PHY. The vehicle showed negligible clotlysis (2.86 ± 4.33%) capacity, while the standard SK (100 I.U.) showed 78.96 ± 1.08% clotlysis activity. Conclusion: NSO and/or PHY exhibited clotlysis activity in human clotted blood in in vitro.
Click on an image to view it in the image viewer
There are no comments for this item.